UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000029046
Receipt number R000033223
Scientific Title The retrospective study of inhibitory effect on optic disc hemorrhage of anti glaucoma drugs
Date of disclosure of the study information 2017/09/07
Last modified on 2017/09/07 18:16:41

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The retrospective study of inhibitory effect on optic disc hemorrhage of anti glaucoma drugs

Acronym

Inhibitory effect of anti glaucoma drugs on optic disc hemorrhage

Scientific Title

The retrospective study of inhibitory effect on optic disc hemorrhage of anti glaucoma drugs

Scientific Title:Acronym

Inhibitory effect of anti glaucoma drugs on optic disc hemorrhage

Region

Japan


Condition

Condition

Glaucoma

Classification by specialty

Ophthalmology Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This retrospective study aims to evaluate the effect of anti glaucoma drugs excluded 0.1% brimonidine on optic disc hemorrhage(DH) in the glaucoma patients with a history of DH.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Comparison with the frequency of DH before and after addition of anti glaucoma ophthalmic solution

Key secondary outcomes

1) Ratio of frequency of DH occurence
2) Intraocular pressure with Goldmann applanation tonometer


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)Patients being treated for more than two years.
2)Patients administered with additional anti glaucoma ophthalmic solution for more than one year.
3)Patients with optic disc hemorrhage before administration of additional anti glaucoma ophthalmic solution
4)Patients who had no addition or change with glaucoma therapeutic drugs in the peroid between the day of anti glaucoma ophthalmic solution addition and the end date of observation period. (If both eyes constitute indication, worse eye is chosen.)

Key exclusion criteria

1)Patients with retinal disease.
2)Patients with corneal opacity.
3)Patients who underwent LASIK surgery.
4)Patients who are undergoing glaucoma surgery within the observation period since the addition of anti glaucoma ophthalmic solution
5) Patients who were inability to take visual field test in accuracy 6)Patients with MD value -25dB or below.

Target sample size

40


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Koji Nitta

Organization

Fukui-ken Saiseikai Hospital

Division name

Ophthalmology

Zip code


Address

Funabashi7-1, Wadanakamachi, Fukui city, Fukui

TEL

0776-23-1111

Email

nitta.koji7001@fukui.saiseikai.or.jp


Public contact

Name of contact person

1st name
Middle name
Last name Koji Nitta

Organization

Fukui-ken Saiseikai Hospital

Division name

Ophthalmology

Zip code


Address

Funabashi7-1, Wadanakamachi, Fukui city, Fukui

TEL

0776-23-1111

Homepage URL


Email

nitta.koji7001@fukui.saiseikai.or.jp


Sponsor or person

Institute

Fukui-ken Saiseikai Hospital

Institute

Department

Personal name



Funding Source

Organization

Senju Pharmaceutical Co.,Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor

Shimamoto Ophthalmology Clinic (Fukui)

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

福井県済生会病院 島本眼科医院 Fukui-ken Saiseikai Hospital Shimamoto Ophthalmology Clinic (Fukui)


Other administrative information

Date of disclosure of the study information

2017 Year 09 Month 07 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2016 Year 11 Month 18 Day

Date of IRB


Anticipated trial start date

2016 Year 12 Month 14 Day

Last follow-up date

2017 Year 04 Month 24 Day

Date of closure to data entry

2017 Year 07 Month 03 Day

Date trial data considered complete

2017 Year 07 Month 28 Day

Date analysis concluded

2017 Year 08 Month 21 Day


Other

Other related information

nothing


Management information

Registered date

2017 Year 09 Month 07 Day

Last modified on

2017 Year 09 Month 07 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033223


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name